H11-CAG-LSL-Myc

品系全名

C57BL/6JSmo-Igs2em1(CAG-LSL-Myc)Smoc

目录号

NM-KI-00039

品系状态

活体

导出PDF

品系描述

c-Myc基因（也叫Myc）在许多肿瘤中存在着异常表达，影响细胞增殖、生长代谢、基因的不稳定性、刺激血管生成、细胞恶性转化、分化及调亡中起着极为重要的调节作用。将CAG promoter-loxp-STOP-loxp-Myc-polyA条件性过表达结构插入到H11位点，建立H11-LSL-Myc小鼠模型。H11位点位于小鼠11号染色体，该位点已被证明与Rosa26类似，可用于较为广泛地表达外源基因。H11-LSL-Myc可在与Cre工具鼠交配后，在Cre表达的组织中高表达Myc基因。可用于肿瘤模型的建立与肿瘤研究中。例如，与Alb-cre小鼠交配后，可在2个月时自发肝癌。
应用领域：肿瘤模型的建立、肿瘤研究

验证数据

大体拍照

图片1.png

Figure1：#79与#88小鼠合影

#88为Alb-Cre小鼠，腹部平坦，腹腔未见明显肿胀等异常现象；#79为MycLSL；Alb-Cre小鼠，腹部膨隆，表面不平，腹腔内可见明显团块状物体充盈。


肝脏组织HE染色结果

图片3.png

Figure2：#79和#88小鼠肝脏组织学结果

#88小鼠的肝脏组织肝细胞呈放射状排列，细胞轮廓清晰，胞核圆形居中，肝小叶结构清晰，组织结构基本正常；#79小鼠的肝脏组织细胞排列无序，胞核不清，可见空泡样变性结构，肝小叶结构消失，组织结构呈不规则细胞团，符合肿瘤组织结构特征。


肝脏组织Ki67IF染色结果

图片4.png

Figure3：#79和#88小鼠肝脏Ki67表达结果

#88小鼠的肝脏组织有散在的Ki67阳性细胞，提示肝脏组织少量细胞有分裂增殖；#79小鼠的肝脏组织有大量的Ki67阳性细胞，提示肝组织的细胞分裂增殖旺盛，符合肿瘤组织的特性。


myc-luci-alb.png

Figure4 活体成像检测荷瘤小鼠（野生型B6小鼠接种了H11-LSL-Myc； Rosa26-LSL-Luc-EGFP； Alb-Cre三阳性小鼠自发肝癌瘤块）的luciferase的表达情况。随着时间推移，荧光强度随着肿瘤增大而逐渐增强


发表文献 13篇

1. Fibrates Inhibit PLTP-induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs
发表年份：2025 来源杂志：Advanced Science

2. Novel humanized monoclonal antibodies against ROR1 for cancer therapy
发表年份：2024 来源杂志：Molecular Cancer

3. Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma
发表年份：2024 来源杂志：Cellular & Molecular Immunology

4. Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors
发表年份：2024 来源杂志：Nature Communications

5. A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma
发表年份：2024 来源杂志：CELL DEATH AND DIFFERENTIATION

6. A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma
发表年份：2024 来源杂志：Cell Reports

7. Loss of Mettl3 enhances liver tumorigenesis by inducing hepatocyte dedifferentiation and hyperproliferation
发表年份：2023-07-25 来源杂志：Cell Reports

8. SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity
发表年份：2023 来源杂志：Nature Communications

9. NFAT1 Orchestrates Spinal Microglial Transcription and Promotes Microglial Proliferation via c-MYC Contributing to Nerve Injury-Induced Neuropathic Pain
发表年份：2022 来源杂志：Advanced Science

10. A multiple functional supramolecular system for synergetic treatments of hepatocellular carcinoma
发表年份：2022 来源杂志：INTERNATIONAL JOURNAL OF PHARMACEUTICS

11. N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism
发表年份：2021 来源杂志：Nature Communications

12. miR-7/TGF-β2 axis sustains acidic tumor microenvironment-induced lung cancer metastasis
发表年份：2021 来源杂志：Acta Pharmaceutica Sinica B

13. A method to establish a c-Myc transgenic mouse model of hepatocellular carcinoma
发表年份：2020 来源杂志：MethodsX

展开

你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看

Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看